Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NGNE
stocks logo

NGNE

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-1.102
+11.31%
--
--
-1.225
+13.43%
--
--
-1.265
+20.48%
Estimates Revision
The market is revising No Change the revenue expectations for Neurogene Inc. (NGNE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 6.07%.
EPS Estimates for FY2025
Revise Downward
down Image
-11.1%
In Past 3 Month
Stock Price
Go Up
up Image
+6.07%
In Past 3 Month
Wall Street analysts forecast NGNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGNE is 58.00 USD with a low forecast of 46.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast NGNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGNE is 58.00 USD with a low forecast of 46.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 21.160
sliders
Low
46.00
Averages
58.00
High
70.00
Current: 21.160
sliders
Low
46.00
Averages
58.00
High
70.00
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$65 -> $70
2025-11-13
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$65 -> $70
2025-11-13
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Neurogene (NGNE) to $70 from $65 and keeps a Buy rating on the shares. The firm believes the new NGN-401 data "highlights an absurdly inverted valuation dynamic" between Taysha Gene Therapies (TSHA) and Neurogene. Taysha still trades at multiples of Neurogene's valuation "despite the fact that NGN-401 has more advanced, durable, and clinically meaningful data," the analyst tells investors in a research note. The firm says Taysha's TSHA-102 still has no longitudinal patient-level detail and no evidence of accumulating multi-skill gains.
H.C. Wainwright
Buy
upgrade
$45 -> $65
2025-10-31
Reason
H.C. Wainwright
Price Target
$45 -> $65
2025-10-31
upgrade
Buy
Reason
H.C. Wainwright raised the firm's price target on Neurogene to $65 from $45 and keeps a Buy rating on the shares. The firm says a pediatric neurologist it spoke to sees "clean" safety, same vector/dose, and clearer regulatory footing for NGN-401. H.C. Wainwright upped its probability of sucess to 45% from 35%.
Craig-Hallum
initiated
$50
2025-06-18
Reason
Craig-Hallum
Price Target
$50
2025-06-18
initiated
Reason
Craig-Hallum initiated coverage of Neurogene with a Buy rating and $50 price target.
BMO Capital
Outperform
maintain
$22 -> $26
2025-06-12
Reason
BMO Capital
Price Target
$22 -> $26
2025-06-12
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Neurogene to $26 from $22 and keeps an Outperform rating on the shares. BMO notes that the initial analysis of the most recently dosed 5 patients with NGN-401 was able to demonstrate ferritin control with no patients surpassing the 500 ng/mL level of clinical concern for HLH, hemophagocytic lymphohistiocytosis, and the firm states that it has more confidence in the company's ability to control reactions going forward, the analyst tells investors in a research note.
BMO Capital
Outperform
maintain
$16 -> $22
2025-05-20
Reason
BMO Capital
Price Target
$16 -> $22
2025-05-20
maintain
Outperform
Reason
BMO Capital raised the firm's price target on Neurogene to $22 from $16 and keeps an Outperform rating on the shares. The firm notes that the company's ASGCT presentations and the recent FDA earnings commentary gives it increased confidence in acceptance of non-placebo controlled trials, the analyst tells investors in a research note. Additional ASGCT presentations outline risk mitigation strategies which makes BMO more confident going forward, the firm added.
Baird
Baird
Outperform -> Neutral
downgrade
$38 -> $24
2025-05-16
Reason
Baird
Baird
Price Target
$38 -> $24
2025-05-16
downgrade
Outperform -> Neutral
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Neurogene Inc (NGNE.O) is -4.32, compared to its 5-year average forward P/E of -6.11. For a more detailed relative valuation and DCF analysis to assess Neurogene Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.11
Current PE
-4.32
Overvalued PE
-3.48
Undervalued PE
-8.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
118.66
Current PS
0.00
Overvalued PS
439.42
Undervalued PS
-202.10
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

NGNE News & Events

Events Timeline

(ET)
2025-11-13
17:12:29
Neurogene announces Q3 earnings per share of 99 cents, compared to a loss of $1.19 in the same period last year.
select
2025-11-12 (ET)
2025-11-12
16:08:32
Neurogene Releases Interim Findings from NGN-401 Trial in Pediatric Group
select
2025-11-06 (ET)
2025-11-06
09:40:13
Neurogene Administers First Dose to Patient in NGN-401 Clinical Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.5
11-14Newsfilter
Neurogene Announces Financial Results for Q3 2025 and Shares Recent Developments

  • Positive Clinical Data: Neurogene reported promising interim results from the NGN-401 Phase 1/2 gene therapy trial for Rett syndrome, showing durable gains in developmental milestones across eight pediatric participants.

  • Embolden Trial Initiation: The first participant has been dosed in the Embolden™ registrational trial for NGN-401, with full enrollment anticipated within three to six months.

  • Financial Position: Neurogene has a strong cash position of $265.4 million, expected to fund operations through the first quarter of 2028, despite a net loss of $21 million for the third quarter of 2025.

  • Innovative Gene Therapy Approach: NGN-401 utilizes Neurogene's proprietary EXACT™ transgene regulation technology to deliver the MECP2 gene, aiming to optimize therapeutic levels while minimizing toxicity, and has received multiple designations from regulatory agencies.

[object Object]
Preview
6.0
11-13Benzinga
HC Wainwright & Co. Reaffirms Buy Rating on Neurogene, Increases Price Target to $70

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.

  • Market Winning Tools: The platform provides essential tools and information to help traders succeed in the stock market.

[object Object]
Preview
9.0
11-06Newsfilter
Neurogene Doses First Participant in Embolden™ Trial for NGN-401 Gene Therapy Targeting Rett Syndrome

  • Trial Initiation: Neurogene has initiated the Embolden™ clinical trial for NGN-401, a gene therapy for Rett syndrome, with the first participant dosed and 12 of 13 clinical sites operational, aiming to complete enrollment in three to six months.

  • Therapeutic Potential: NGN-401 is designed to deliver the full-length MECP2 gene and is expected to be a best-in-class treatment for Rett syndrome, addressing significant unmet medical needs in patients aged three and older.

  • Upcoming Data Presentation: Interim data from the Phase 1/2 trial of NGN-401 will be presented by Neurogene management at the Stifel Healthcare Conference on November 12, 2025.

  • Regulatory Designations: NGN-401 has received multiple designations from the FDA and EMA, including RMAT and PRIME designations, highlighting its potential as a significant advancement in gene therapy for Rett syndrome.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Neurogene Inc (NGNE) stock price today?

The current price of NGNE is 21.16 USD — it has increased 5.17 % in the last trading day.

arrow icon

What is Neurogene Inc (NGNE)'s business?

Neurogene Inc. is a clinical-stage biotechnology company. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is in development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. It is also developing NGN-101 for the treatment of CLN5 Batten disease.

arrow icon

What is the price predicton of NGNE Stock?

Wall Street analysts forecast NGNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NGNE is 58.00 USD with a low forecast of 46.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Neurogene Inc (NGNE)'s revenue for the last quarter?

Neurogene Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Neurogene Inc (NGNE)'s earnings per share (EPS) for the last quarter?

Neurogene Inc. EPS for the last quarter amounts to -0.99 USD, decreased -16.81 % YoY.

arrow icon

What changes have occurred in the market's expectations for Neurogene Inc (NGNE)'s fundamentals?

The market is revising No Change the revenue expectations for Neurogene Inc. (NGNE) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 6.07%.
arrow icon

How many employees does Neurogene Inc (NGNE). have?

Neurogene Inc (NGNE) has 107 emplpoyees as of December 05 2025.

arrow icon

What is Neurogene Inc (NGNE) market cap?

Today NGNE has the market capitalization of 327.14M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free